HISTAMINE-H2 ANTAGONISTS IN ACUTE UPPER GASTROINTESTINAL HEMORRHAGE - REPLY Por Collins, R, Langman, M

Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. Por Collins, R, Langman, M

Communication among health professionals. Poor communication puts patients at risk. Por Salter, R, Brettle, P, Hobbs, F, Langman, M

Communication among health professionals (multiple letters) [2] Por Salter, R, Brettle, P, Hobbs, R, Langman, M, Crimlisk, H

VICTOR: A phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection Por Kerr, D, Dunn, J, Langman, M, Smith, J, Midgley, R, Iveson, C, McConkey, C

VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION Por Midgley, R, McConkey, C, Langman, M, Smith, J, Julier, P, Iveson, C, Johnstone, E, Chen, X, Dunn, J, Kerr, D, Grp, V

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. Por Kerr, D, Dunn, J, Langman, M, Smith, J, Midgley, R, Stanley, A, Stokes, J, Julier, P, Iveson, C, Duvvuri, R, McConkey, C

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. Por Midgley, R, McConkey, C, Johnstone, E, Dunn, J, Smith, J, Grumett, SA, Julier, P, Iveson, C, Yanagisawa, Y, Warren, B, Langman, M, Kerr, D